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The Bergen 4-day treatment (B4DT) for obsessive-compulsive disorder (OCD) was
recently tested in a randomized controlled trial, where the results showed that the B4DT
was more effective than a self-help intervention (SH) and a waiting list condition (WL).
Patients in the SH and WL condition still in need of treatment after the first intervention
(N = 26; 13 from each condition) were offered the B4DT. None of the patients declined
participation, and there were no dropouts. At post-treatment 59.5% were in remission,
31.0% had treatment response, and 9.5% showed no change. At 3-month follow-up
71.4% were in remission, 19.0% had treatment response, and 9.5% showed no change.
There were also significant improvement in self-reported symptoms of OCD, generalized
anxiety symptoms, and depressive symptoms. The results are in line with what we
previously have found for the B4DT in a number of effectiveness studies. In addition,
the results indicate that the patients who previously had received an unsuccessful SH
intervention and patients who had first been in a WL condition, profited as much as
patients who had received the B4DT as the initial intervention. Implications for clinical
guidelines and for dissemination of the B4DT are discussed.
Keywords: obsessive-compulsive disorder, ERP, RCT, B4DT, self-help, waiting list, follow-up
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a disabling disorder characterized by recurrent, unwanted
thoughts, images, or urges (obsessions) and/or repetitive behaviors or thoughts (compulsions)
(American Psychiatric and Association, 2013). Cognitive behavioral therapy (CBT) with exposure
and response prevention (ERP) is a well-established treatment for patients with OCD (Rosa-
Alcázar et al., 2008; Öst et al., 2015). Meta-analyses (e.g., Öst et al., 2015) of randomized controlled
trial (RCT) suggest that approximately 65% of patients achieve a reliable treatment response
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and 50% are in remission following treatment. Treatment
can be given individually and in groups and with different
intensity and the results are quite similar (Rosa-Alcázar et al.,
2008; Olatunji et al., 2013; Öst et al., 2015). Several studies
suggest that intensive (in- and outpatient) treatment could
be effective in treating adults with OCD (Jónsson et al.,
2015; Veale et al., 2016), but also for children with anxiety
(Öst and Ollendick, 2017). These treatments are, however,
often not available for the patients (Shafran et al., 2009).
The National Institute for Health and Care Excellence (NICE,
2005) thus recommends a stepped care model where the first
intervention is “brief individual CBT (including ERP) using
structured self-help materials” since these approaches can be
easily disseminated. Self-help interventions are documented
effective, although with smaller effect sizes than face-to-face
treatment (Pearcy et al., 2016).
Since 2012, the OCD-team in Bergen, Norway, has developed a
highly concentrated exposure based treatment format for patients
with OCD, the Bergen 4-day treatment (B4DT). During four
consecutive days, OCD patients receive individually tailored
and therapist assisted exposure treatment delivered in a group
setting, where the patient–therapist ratio is 1:1. The approach
is highly attractive to the patients, and there is basically no
attrition. A number of open trials indicate that more than 90%
of the patients can expect to respond to treatment with nearly
70% being recovered 1–4 years after participating in the B4DT
(Hansen et al., 2018, 2019). The B4DT has also been piloted
outside the Bergen group (Kvale et al., 2018; Launes et al.,
2019a,b), and in a different country (Davíðsdóttir et al., 2019),
with the same results.
Recently, the first randomized controlled trial (RCT) of the
B4DT was completed (Launes et al., 2019b), where it was
compared to a self-help (SH) intervention as well as a waiting
list (WL) condition. Results showed that 93.8% responded to
treatment in the B4DT condition. For patients in the SH
condition, 12.5% responded, while none of the patients on WL
had a treatment response. At 3-month follow-up, 69% were
remitted and 31% were improved. At 6-month after treatment,
81% were in remission, 6% were improved, and 13% unchanged.
Thus, the first controlled trial of the B4DT supported the positive
findings from the open trials.
The patients who were in need of further treatment after
the SH or WL condition were offered the B4DT, which
implies that for the patients who first received the SH, the
National Institute for Health and Care Excellence (NICE,
2005) guidelines of a stepped care approach were followed.
Clearly, the NICE recommendations assume that patients who
have first received unsuccessful SH are not at a disadvantage
when they proceed to a therapist-assisted intervention, but
the documentation for this is sparse. Thus, in the current
article we will investigate the following questions: (1) Are
clinical changes after the B4DT also seen in the patients
with prior experience of SH or a WL, and are the changes
maintained at 3-month follow-up? (2) Do the patients who
had received an unsuccessful SH treatment profit as much




From 2016 to 2017 a randomized controlled trial (RCT) was
conducted at Solvang Community Psychiatric Service (Sørlandet
Hospital) in Norway (Launes et al., 2019b). The RCT compared
the effects of B4DT to the effects of a SH intervention and a
WL. Included participants consisted of consecutive referrals to
a specialized OCD-team at the hospital. Patients were referred
from their general practitioner or their local outpatient clinic.
Referrals were based upon a suspicion of OCD.
The inclusion criteria for the study were: (a) signed informed
consent, (b) ≥18 years, (c) met DSM-5 criteria for OCD,
(d) Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score
≥16, and (e) spoke Norwegian fluently. The exclusion criteria
for the study were: (a) meeting DSM-5 criteria for bipolar
disorder, psychosis, or ongoing substance abuse/dependence, (b)
intellectual disability based on previous medical history, (c) an
eating disorder in need of medical attention, (d) not willing to
refrain from anxiolytics during treatment, (e) ongoing suicide
ideation, (f) SSRI-treatment initiated or dosage changed during
the last four weeks before starting treatment, and (g) living
far away from the treatment center (>1.5 h). Patients with
prior CBT for OCD were not included due to a nationwide
trial targeting this population. The patients who were not
helped after a SH condition or a WL were offered the B4DT
(Launes et al., 2019b). A flow-chart of the study is presented in
Figure 1.
Two of the patients who had received the SH intervention
had improved according to their own evaluations and did not
want further treatment and one patient who had received SH
moved to another part of the country. Thus, 13 patients in the
previous SH condition started treatment with the B4DT. Of the
15 patients who previously completed the WL condition, one
moved to another part of the country, and another received
inpatient treatment due to pregnancy complications, leaving 13
patients who started the B4DT. All patients who had received
B4DT as the immediate intervention (n = 16) function as a
comparison condition at follow-up. The 26 patients who had
received either WL or SH condition were assigned to the first
available B4DT group.
Background Data
Table 1 displays a summary of the participants’ demographic
data, diagnostic information and pharmacological treatment.
There was no difference in pre-treatment Y-BOCS scores between
patients who had previously been in the SH or the WL condition,
F(1,24) = 0.121, p = 0.731. In addition, there were no significant
differences between these two groups on any other pre-treatment
variable. All patients but one were classified as having severe OCD
(Y-BOCS score of 24 or more) at pre-treatment.
The patients’ use of medication was recorded at the initial
interview. Patients using benzodiazepines discontinued these
prior to treatment. Compliance was confirmed in the post-
treatment assessment. Patients had no other treatment during the
four days, as confirmed by medical records.
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FIGURE 1 | Flow chart.
Assessment
Patients had a diagnostic- (First et al., 2015) and Y-BOCS
interview with an independent assessor by phone one week
prior to starting treatment. Patients were re-assessed by an
independent assessor within one week after completing treatment
and at 3-month follow-up. For further procedural details
regarding the RCT, please refer to Launes et al. (2019b). Following
the assessment after three months of SH or WL, patients
who wanted further treatment were offered participation in a
B4DT group. The assessment procedures were the same for the
patients that first received SH or WL. Inter-rater reliability was
checked with respect to OCD diagnosis and Y-BOCS. For the
OCD diagnosis the kappa value was 1.00, while the intra-class
correlation for Y-BOCS was 0.97.
Measures
OCD symptoms
The Y-BOCS (Goodman et al., 1989a,b) is a 10-item interview,
and was used as the primary outcome measure in this
study. Ten items are rated on a 0–4 scale, and total score
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TABLE 1 | Background characteristics of the combined waiting list- and self-help
condition (N = 26).
M (SD)
Age 28.08 (6.69)
Age of OCD onset 13.19 (7.44)






On social benefits 12 (46.2)
OCD in the family 8 (30.8)
Psychotropic medication 11 (42.3)
Any comorbid disorder 24 (92.3)
Comorbid depression 14 (53.8)
Comorbid anxiety 16 (61.5)
Other comorbidity 10 (38.5)
Three patients had five comorbid disorders, six had four, four had three, seven
had two, and four patients had one comorbid disorder. The “other comorbidity”
category included bulimia, insomnia, ADHD, and skin picking. There were no
significant differences between the SH and WL group on these variables, except
for “other comorbidity” where the WL group had slightly more disorders than the
SH group (χ2 = 5.85, p = 0.016).
ranges from 0 to 40. Psychometric properties are good
(Goodman et al., 1989a,b).
Two self-report measures of OCD symptoms were also
included. The Dimensional Obsessive Compulsive Scale Short-
Form (DOCS-SF; Eilertsen et al., 2017) is a five item version of the
original 28-item version of DOCS (Abramowitz et al., 2010). The
five items are rated on a scale from 0 to 8 and concern time spent,
avoidance, distress, interference with functioning, and difficulty
disregarding obsessions and refraining from compulsions. The
total score ranges from 0 to 40.
The second self-report measure of OCD symptoms was the
Obsessive-Compulsive Inventory-Revised (OCI-R; Foa et al.,
2002), an 18-item scale. Items are rated on a 0–4 scale, and total
score range from 0 to 72. The OCI-R has good psychometric
properties (Foa et al., 2002; Solem et al., 2010).
In adition to measures of OCD-symptoms, the study included
measures of comorbid symptoms of depression and generalized
anxiety. The Patient Health Questionnaire-9 (PHQ-9; Kroenke
et al., 2010) is a 9-item scale assessing symptoms of depression.
Items are rated on a 0–3 scale, and total score ranges from
0 to 27. The PHQ-9 has sound psychometric properties
(Kroenke et al., 2010).
The Generalized Anxiety Disorder Scale (GAD-7; Spitzer
et al., 2006) is a 7-item scale assessing symptoms of generalized
anxiety. Items are rated on a 0–3 scale, and total score ranges
from 0 to 21. Psychometric properties of the GAD-7 are good
(Spitzer et al., 2006; Beard and Bjorgvinsson, 2014; Rutter and
Brown, 2017).
In addition to the symptom scales, we also included a
measure of satisfaction with treatment. The Client Satisfaction
Questionnaire 8 (CSQ-8; Nguyen et al., 1983) is an 8-item
scale assessing satisfaction with treatment received. Items are
rated on a 0–4 scale, and total score ranges from 8 to 32.
Psychometric properties of the CSQ-8 are good (Larsen et al.,
1979; Nguyen et al., 1983).
Therapists
There were equal number of patients and therapists in
each group, and each group was led by an expert on the
treatment format. All therapists were trained in delivering
the treatment (Kvale and Hansen, 2014). Prior to acting as a
B4DT therapist, each had been evaluated as competent by two
independent assessors in a minimum of two B4DT groups.
Specific competencies in conducting the LET-intervention (see
below) were evaluated by a B4DT expert watching videotaped
sessions. The leaders of the groups had participated as therapists
in at least six B4DT groups in order to be certified as competent.
Then they acted as leaders of a minimum of two B4DT groups
prior to the trial. Therapists in the present study included five
psychologists, two psychiatric nurses, and two psychiatrists.
The B4DT Format
A detailed description of the treatment format is given in
Launes et al. (2019b). Prior to the treatment, the patients were
provided with oral and written information about the content
of the four days.
The LET-Technique
Prior to exposure treatment, patients are taught to pay close
attention to the way the exposures are done, and one of
the main features of the 4-day treatment, namely the “LEan
into The anxiety” (LET-technique) is demonstrated. Patients
have to approach stimuli that elicit anxiety/discomfort and act
in a manner that is incompatible with their OCD. During
the two days of exposure treatment, the patients are assisted
when they practice the LET-technique, and encouraged and
assisted to employ the approach in all situations that elicit
anxiety/discomfort.
Day 1, Psychoeducation and Treatment Preparation
(3–4 h)
Participants receive psychoeducation in which they are provided
with explanations for the treatment and for the techniques that
are seen as essential. The psychoeducation is manualized using
a PowerPoint presentation with a text-file detailing the content
to be presented. The patients share their suggested exposure tasks
with the group, and individual plans are made together with input
from the group leader.
Day 2 and 3, (8 h + 1.5 h Psychoeducation for Family)
Throughout Day 2 and 3, patients practice individually tailored
and therapist assisted ERP. In the evening patients are to
continue with self-administrated training. Exposure sessions are
interspaced with brief group meetings where each patient share
their ratings of their own exposure performance with the group.
They evaluate their own LET-performance on a 1–6 scale. A score
of 6 indicates that they were “leaning fully into” the anxiety.
Scores below 6 are explored by the group leader, and the
patients are given advice and encouragement aimed at giving
them courage to “not hold back” in the next exposure. Patients
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were given the opportunity to invite relatives and friends to a
psychoeducation session in the afternoon of day 3.
Day 4, Summarizing and Relapse Prevention
Day 4 is used for summarizing and planning self-exposures
for the next three weeks. Patients are taught to be their own
therapists. They make their own exposure plans to be performed
the first three weeks after the treatment. Written information
concerning procedures and upcoming assessments is handed out,
and the group ends with the patients providing feedback on their
experiences with treatment.
Homework Assignments and Follow-Up Visit
Patients log homework (exposures) completed for a 3-week
period after treatment. About 12 weeks after treatment, patients
meet for an individual follow-up session at the clinic. This session
is intended to help the patient summarize their experiences
after completing treatment, and if necessary, to refresh the
treatment principles. This follow-up session did not involve
exposure exercises.
Classification of Treatment Response
and Remission
An adaptation of the international consensus criteria was used
for assessing treatment response (Mataix-Cols et al., 2016), not
including the criterion for change in Clinical Global Impression.
A treatment response involves a ≥35% reduction in Y-BOCS
score. Remission is defined as meeting the treatment response
criterion as well as having a post-treatment or follow-up Y-BOCS
score of 12 or less.
Statistical Analysis
There were few instances of missing data. For Y-BOCS and
the self-report scales there were four patients missing data at
post-treatment-2. However, all four patients attended the follow-
up assessment, and their scores from follow-up were therefore
carried backward to replace their missing post-treatment-2 score.
Imputation using “next observation carried backward” is one of
the imputation methods giving least bias in scores (Mundahl
Engels and Diehr, 2003). There was only one patient missing
self-report data at follow-up. This patient was given his/her
post-treatment score as follow-up score (last observation carried
forward). One patient had missing data on the CSQ-8, which
was not replaced.
Paired sample t-tests were first used to investigate if
the SH or WL groups had any significant improvement on
Y-BOCS scores (post-treatment-1). Paired sample t-tests
were also used to investigate whether the two groups had
a significant improvement after being given the B4DT at
post-treatment-2 and 3-month follow-up. Independent
sample’s t-tests were used to compare the two groups at
post-treatment-2 and follow-up. Possible differences in
change scores (from pre-treatment to post-treatment-2 and
follow-up) between participants given immediate B4DT
and delayed B4DT were also compared using independent
samples t-tests.
Treatment outcome was further analyzed using repeated
measures ANOVA with three different times of assessment (pre-
treatment, post-treatment, and follow-up). This analysis was
used for all outcome measures (Y-BOCS, PHQ-9, GAD-7, OCI-
R, and DOCS-SF).
RESULTS
A summary of the Y-BOCS scores for the SH- and WL-conditions
is displayed in Table 2. Paired sample t-tests showed that
there was no significant effect of the WL at post-treatment-1,
while there was a significant but small improvement observed
for the SH-condition. The patients then received the B4DT
after the post-treatment-1 assessment. Irrespective of which
original condition the patients belonged to they achieved a
very large and significant improvement at the post-treatment-
2 assessment. The change scores (pre-treatment to post-
treatment 2/follow-up), was not significantly different between
the conditions at post-treatment 2; t(24) = 0.164, p = 0.871,
or at follow-up; t(24) = 0.35, p = 0.73. Participants from the
two groups were therefore merged together into one group for
further analyses.
Change in Y-BOCS scores after being given the B4DT was
compared between patients given immediate B4DT (N = 16)
and patients originally in the SH or WL condition (N = 26).
The immediate B4DT group had a mean change score of 15.85
(5.85) at post-treatment compared to 16.31 (4.52) for the SH/WL
patients, t(40) = 0.287, p = 0.775. There were also a non-
significant difference at follow-up, as immediate B4DT showed
a mean change score of 18.19 (5.95) compared to 17.58 (7.18)
for the WL/SH group, t(40) = 0.285, p = 0.777. Thus, for
the analysis of clinical change all patients were combined into
TABLE 2 | Y-BOCS means (SDs) for the two groups at the four assessment points.
Pre Post-1 Post-2 3m F-U Pre–Post-1 Pre–Post-2
Y-BOCS M (SD) t p t p
Immediate B4DT (n = 16) 26.75 (4.23) 10.90 (4.35) 8.56 (5.75)
WL (n = 13) 27.08 (3.59) 26.77 (4.04) 10.62 (2.22) 10.00 (5.85) 0.39 0.71 12.87 <0.0001
SH (n = 13) 29.15 (3.46) 26.85 (3.26) 12.99 (3.59) 11.08 (6.09) 2.93 0.01 12.62 <0.0001
Y-BOCS, Yale-Brown Obsessive Compulsive Scale; B4DT, Bergen 4-day treatment; WL, waiting list; SH, self-help; Pre, pre-treatment; Post-1, post-treatment after WL or
SH; Post-2, post-treatment after B4DT; 3m F-U, 3-month follow-up after B4DT.
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The clinical improvements at post-treatment and follow-
up are presented in Table 3. Of the 42 patients given
the B4DT, 25 (59.5%) were remitted at post-treatment, 13
(31.0%) had a treatment response, and 4 (9.5%) showed
no change. At 3-month follow-up 30 patients (71.4%) were
remitted, 8 (19.0%) had a treatment response, and 4 (9.5%)
showed no change. The 25 patients classified as remitted
at post-treatment had a stable improvement as 24 (96%)
were still remitted at follow-up, while one patient was now
classified as a treatment responder. In other words, there
were no clear signs of relapse. There were 13 patients
classified as having treatment response at post-treatment,
and of these five (38%) achieved remission at follow-up,
five remained responders, while three showed no change
at follow-up. Four patients were classified as having no
change at post-treatment, and of these one patient achieved
remission at follow-up, two were classified as treatment
responders, and one was still classified as having no change. No
patients deteriorated.
Secondary Outcome Measures
Table 4 displays the results for Y-BOCS and secondary outcome
measures at pre-treatment, post-treatment, and 3-month follow-
up. Repeated measures ANOVA found a significant effect of
time for all five measures. The effect size was highest for
change in OCD measures and lowest (but moderate) for
change in depression.
Additional Analyses
Patients using psychotropic medication did not differ on
OCD-severity at pre-treatment, t(24) = 0.33, p = 0.74, from
those not taking such medication. However, they showed
tendencies toward having higher Y-BOCS scores at post-
treatment (M = 13.2, SD = 4.0 vs. M = 10.8, SD = 1.9) and
follow-up (M = 13.0, SD = 6.6 vs. M = 8.7, SD = 4.8), p = 0.048 and
p = 0.066, respectively. Similar observations were made for the
DOCS-SF data, but not for the other outcome measures (PHQ-
9, GAD-7, and OCI-R). There were no significant differences in
client satisfaction scores, t(22) = 0.09, p = 0.93.
Treatment Satisfaction
Data on treatment satisfaction is presented in Table 5. The
majority (96%) were happy with the quality of service, and
all participants would have recommended it to a friend with
a similar condition. All participants also rated the overall
satisfaction with the treatment as positive. The mean satisfaction
score of 28.96 (SD = 3.06) was comparable to patients in the
immediate B4DT condition who scored 29.69 (SD = 2.62), a
non-significant difference.
DISCUSSION
The present study was a follow-up of a recently conducted RCT
for OCD where the experimental group was treated with the
newly developed B4DT and the two control conditions consisted
of patients that either were allocated to SH or WL. The results
from the controlled trial (Launes et al., 2019b) showed that
compared to SH- and WL-participants the patients in the B4DT
reported significantly lower scores on OCD severity, depression,
TABLE 3 | Clinical improvement rates for B4DT at post-treatment and follow-up.
3-month follow-up Total
Remission Response No change Deterioration
Post-treatment Remission 24 1 0 0 25
Response 5 5 3 0 13
No change 1 2 1 0 4
Deterioration 0 0 0 0 0
Total 30 8 4 0 42
Treatment response was based on a modification of the international consensus criteria (Mataix-Cols et al., 2016). Response: ≥35% reduction in Y-BOCS score.
Remission: meeting the response criterion and a post-treatment/follow-up score of 12 points or less.
TABLE 4 | Means (SDs) and effect sizes for the outcome measures at the various assessment points.
Pre Post FU F p Partial η2 d pre-post d pre-FU
Y-BOCS 27.08 (3.32) 11.80 (3.16) 10.54 (5.87) 136.98 <0.001 0.85 4.60 4.98
DOCS-SF 25.85 (4.49) 17.15 (6.09) 15.00 (9.13) 30.02 <0.001 0.55 1.94 2.42
OCI-R 25.19 (12.88) 16.73 (12.51) 14.85 (13.53) 18.12 <0.001 0.42 0.66 0.80
GAD-7 13.24 (4.32) 9.38 (3.95) 8.12 (4.46) 15.91 <0.001 0.39 0.89 1.19
PHQ-9 12.81 (4.36) 9.88 (3.65) 9.73 (4.90) 6.23 0.004 0.20 0.67 0.71
Test of within subjects, N = 26. Cohen’s d = Mpre–Mpost/SDpre. Mauchly’s test of sphericity was significant for OCI-R, but not for the other measures. Y-BOCS, Yale-Brown
Obsessive Compulsive Scale; DOCS-SF, Dimensional Obsessive Compulsive Scale Short-Form; OCI-R, Obsessive-Compulsive Inventory-Revised; GAD-7, Generalized
Anxiety Disorder Scale; PHQ-9, Patient Health Questionnaire-9.
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TABLE 5 | Patients’ treatment satisfaction with B4DT after initial self-help
or waiting list.
Item Satisfaction rating
1 2 3 4
Quality of service 0 1 10 14
Kind of service 0 0 11 14
Met needs 1 0 15 9
Recommend to friend 0 0 2 23
Amount of help 0 0 10 15
Dealt with problems 0 1 6 18
Overall satisfaction 0 0 11 14
Come back 0 2 3 20
N = 25. Items are scored on a scale from 1 (low satisfaction) to 4 (high satisfaction).
generalized anxiety, as well as higher social and work-related
functioning, at post-treatment. The patients who were in need
of further treatment after SH or WL were offered B4DT, and the
aims of the present study were to investigate if the clinical changes
after B4DT are also seen in patients with prior experience of SH
or a WL, and if patients who had received an unsuccessful SH
treatment improved as much as patients who had received the
B4DT as the initial intervention.
The results indicate that both the patients who had previously
received SH and those in the WL condition benefited significantly
from the B4DT, and that they did not differ in treatment effect at
3-month follow-up from the patients who had received the B4DT
immediately. At post-treatment and follow-up 90.5% showed
a treatment response, and the remission rates were 58% at
post-treatment and 73.1% at follow-up. This corresponds well
with previous research on the B4DT (e.g., Kvale et al., 2018).
Overall, treatment gains made from pre- to post-assessment were
maintained and slightly improved at the 3-month follow-up, with
no difference between the conditions in terms of reduction of
OCD-, depression- and general anxiety symptoms. There were
also no differences in experienced satisfaction with the B4DT
even for the patients that first had been on a WL or participated
in a SH program for OCD.
There are only three studies investigating the effect of stepped
care treatment for OCD, and they suffer from sample size and
attrition issues. In a pilot study of stepped care, 11 patients
started with SH (step 1), followed by self-directed ERP with
minimal therapist contact (step 2) if they did not respond to
the first step of treatment, and step 3 was traditional therapist
directed ERP (Tolin et al., 2005). Of the 11 who started treatment
two patients responded after step 1, two responded after step 2,
and two responded after step 3 (total of 6 responders, 55% of
ITT). Gilliam et al. (2010) also published a small open trial of
stepped care treatment for 14 patients with OCD. Participants
first received self-directed ERP (step 1) followed by therapist-
directed ERP (step 2). In that study, five patients responded
after step 1, while only one patient responded at follow-up (total
response rate of 43% for ITT). Results from step 2 was somewhat
discouraging, however, it is difficult to conclude whether the
first step affected treatment response in step 2. A somewhat
larger and controlled study assigned 19 patients to stepped care
[12 completers, seven (37% of ITT) responders at follow-up],
and 15 assigned to standard ERP [10 completers, three (20%
of ITT) responders at follow-up] (Tolin et al., 2011). The low
treatment response rate still leaves the question as to whether
stepped care is a suitable treatment approach for people with
OCD. Furthermore, since this study dating back to 2011 there
has, to the best of our knowledge, been no study published on
stepped care for OCD. Along with the results of the current study,
there is no clear evidence that stepped care treatment should be
the preferred treatment of choice. However, there is also no clear
evidence that stepped care hinders subsequent interventions.
The results suggest that there should be no methodological
or obvious ethical concerns to first randomize OCD-patients
to 3-month of WL or a SH program before they receive the
B4DT. Given that patients usually have to wait before they receive
treatment, this finding is interesting because it underscores that
it is likely that patients can benefit from the B4DT even if
they do not receive the treatment immediately. This can be of
value, e.g., when patients express an urge to initiate treatment
as soon as possible. Patients who had received SH did not
gain more from the B4DT post-treatment or at follow-up as
compared to the WL-patients. On the other hand, the patients
with prior SH, were not at a disadvantage regarding the benefit
they experienced following the B4DT. It is noteworthy that the
SH was delivered without assistance from a therapist and that
the patients were guaranteed B4DT after the SH treatment if they
needed further treatment.
There are some limitations of the current study such as limited
sample size and lack of long-term follow-up. However, studies
using the B4DT with larger sample sizes and long-term follow-
up assessments have indicated that the results are consistent.
Another limitation concerns the fact that the SH condition
was not assisted. It is likely that assisted SH could yield better
treatment results (Andersson et al., 2012, 2015). Furthermore, it
is unclear what effect the B4DT would have for patients who have
been treated with assisted SH. Although the study included all
consecutive referrals to the clinic, there might, however, be noted
that during the referral period there was an ongoing national
study that targeted specifically patients with OCD that previously
had received CBT. Another limitation concerns the unbalanced
gender distribution. Furthermore, which components of the
4-day format that can be seen as critical for outcome was
not the focus of the current study. However, future research
should consider comparing the B4DT with the same treatment
delivered across 12 weeks with a single therapist and individual
treatment given in the 4-day format. This could allow for
inferences concerning specific components of the treatment such
as the concentration of the treatment and the effects of working
in groups.”
The results from this RCT provide evidence that most OCD
patients treated with B4DT, delivered at another site than
the originators’ clinic, achieve highly comparable outcomes at
post-treatment and 3-month follow-up, as a number of open
trials have reported (Havnen et al., 2014, 2017; Hansen et al.,
2018; Kvale et al., 2018; Davíðsdóttir et al., 2019; Launes
et al., 2019a,b). In addition, the study replicated previous
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findings concerning refusal and attrition rates. Replication
studies on the B4DT format are needed from other sites,
countries and cultures.
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